Our Services
Medical Information
Helpful Resources
Published on: 4/13/2026
Zepbound (tirzepatide) is not recommended during pregnancy, as intentional weight loss may harm fetal development and animal studies suggest potential risks. If you become pregnant while taking Zepbound, contact your clinician immediately and expect to stop the medication. Because tirzepatide stays in the body for weeks, most experts recommend discontinuing Zepbound at least 2 months before trying to conceive and using reliable contraception in the meantime.
Urgent warning signs—such as persistent vomiting, dehydration, or severe abdominal pain—may indicate pancreatitis or gallbladder problems and require immediate medical attention. Considerations around breastfeeding, side effects, and timing also vary from person to person.
Because pregnancy planning while on Zepbound involves personal risk factors, symptoms, and timing that generic advice can't address, taking a free, instant, online symptom check can help you clarify what your symptoms may mean and guide your next steps with confidence.
Reviewed for medical accuracy: 07/10/2026
Weight loss medications like Zepbound® (tirzepatide) are increasingly used to help adults with obesity or overweight manage their weight and improve metabolic health. But if you are pregnant, planning to become pregnant, or could become pregnant, it's essential to understand how this medication may affect you and your baby.
This guide explains what we know about Zepbound side effects, pregnancy safety concerns, and practical next steps—based on credible medical and regulatory guidance.
Zepbound (tirzepatide) is a once-weekly injectable prescription medication approved for chronic weight management in adults with:
Tirzepatide works by activating two hormone receptors:
These hormones help regulate appetite, blood sugar, and digestion. The result is reduced hunger, increased fullness, and often significant weight loss.
However, these same mechanisms can pose concerns during pregnancy.
According to prescribing information and regulatory guidance:
There are no adequate, well-controlled studies in pregnant women, so we do not have definitive human safety data. However, based on animal studies and how the drug works, there is potential risk.
Because of this, Zepbound is generally discontinued if pregnancy occurs.
During pregnancy, your body needs adequate nutrition to support fetal growth. Intentional weight loss can potentially increase the risk of:
Even for people with obesity, the focus during pregnancy is usually on healthy weight gain within recommended guidelines, not weight reduction.
In animal studies of tirzepatide:
While animal results don't always translate directly to humans, they are serious enough that manufacturers and regulatory agencies advise against use during pregnancy.
Understanding Zepbound side effects is important whether you're pregnant or planning to become pregnant.
Common side effects include:
These are usually mild to moderate and often improve over time. However, in pregnancy, symptoms like vomiting and dehydration can become more concerning.
Less common but potentially serious Zepbound side effects include:
If you are pregnant and experiencing severe abdominal pain, persistent vomiting, signs of dehydration, or allergic symptoms, you should seek medical care immediately.
If you discover you are pregnant while on Zepbound:
Because tirzepatide stays in the body for some time, it may take several weeks to fully clear. Many healthcare professionals recommend stopping Zepbound at least two months before attempting to conceive, based on its long half-life.
If you're noticing unusual symptoms and unsure whether they could be related to pregnancy or medication side effects, try Ubie's free AI symptom checker to help identify what might be causing your symptoms and whether you should contact your healthcare provider right away.
If you are of reproductive age and taking Zepbound, consider the following:
Because pregnancy while on Zepbound is not recommended, reliable birth control is important unless you are actively trying to conceive.
Tirzepatide has a long duration in the body. Most experts advise:
This allows the medication to clear sufficiently.
Some GLP-1–based medications may affect how oral contraceptives are absorbed, particularly when starting therapy or increasing doses. Your healthcare provider may recommend:
There is limited human data on how tirzepatide affects fertility.
However:
If your menstrual cycles become more regular while losing weight, your fertility may increase.
It is not known whether tirzepatide passes into human breast milk.
Because:
Zepbound is generally not recommended during breastfeeding unless your doctor determines the benefits outweigh potential risks.
If you have obesity or weight-related health conditions, managing your weight can significantly improve long-term health outcomes, including:
However, during pregnancy, priorities shift toward:
Your healthcare provider can help you:
Certain symptoms while on Zepbound require urgent evaluation, especially during pregnancy:
If you experience symptoms that feel severe, sudden, or life-threatening, seek emergency medical care immediately.
Zepbound can be an effective tool for weight management, but pregnancy changes the equation. The safest approach is proactive planning, open communication with your healthcare provider, and careful monitoring.
If you're experiencing concerning symptoms—whether related to Zepbound side effects or pregnancy—Ubie's free AI symptom checker can provide personalized insights in just a few minutes to help you understand what might be happening and whether medical attention is needed.
Most importantly, speak to a doctor about any symptoms that could be serious or life-threatening. Individual risk factors, medical history, and pregnancy plans matter—and personalized medical advice is always the safest path forward.
(References)
* Al-Badri, M. R., Al-Ghamdi, N. S., Al-Mohannadi, A. S., Al-Sulaiti, M. M., Zubaid, M., Al-Maadheed, A. K., ... & Zaki, M. (2022). GLP-1 receptor agonists in pregnancy: A systematic review and meta-analysis. *Diabetic Medicine*, *39*(5), e14777.
* Lee, M. S., Jang, J. W., Park, B. S., Yoon, Y. J., Kim, G. R., Kim, H. S., & Kim, C. H. (2023). New-Generation Antidiabetic Drugs in Pregnancy: An Update. *Journal of Clinical Medicine*, *12*(14), 4780.
* Butt, A. R., & Kim, C. H. (2023). Pharmacotherapy for Obesity in Pregnancy: A Review of Current Data and Future Directions. *Current Obesity Reports*, *12*(3), 263-270.
* Shah, P. S., Sharma, A., Thunga, G., & Shivakumar, C. H. (2023). Obesity in Pregnancy: Impact of Maternal Obesity on Pregnancy Outcomes and an Approach to Management. *Cureus*, *15*(10).
* Poppe, L., Sanyal, S., Coskun, T., & Haupt, A. (2022). Reproductive and developmental toxicity studies of tirzepatide, a dual GIP and GLP-1 receptor agonist, in rats and rabbits. *Birth Defects Research*, *114*(13), 857-865.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.